To Whom It May Concern
KYORIN Co.,LtdLaunch of Ulcerative Colitis and Crohn’s Disease Therapeutic AgentPentasa® Tablets 500

Tokyo－October 1,2008,KYORIN Co., Ltd. Announces that its wholly owned subsidiary, KYORIN
Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) launched today Pentasa® Tablets
500 as an additional formulation to the Pentasa®250 (generic name :mesalazine) already on the market.
Since July 1996, KYORIN Pharmaceutical Co., Ltd. and Nisshin Kyorin Pharmaceutical Co., Ltd. bothhave marketed Pentasa® Tablets 250 and have contributed to the treatment of ulcerative colitis andCrohn’s disease.
Pentasa® Tablets 500 lessen the burden on patients by reducing the number of tablets currently
marketed Pentasa® Tablets 250 that are administered per day. Pentasa® Tablets 500 were developed forthe purpose of improving adherence* as well as QOL.
To distinguish them from the round Pentasa® Tablets 250, Pentasa® Tablets 500 came in a capsuleform.
Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) are intractable diseases thathinder social interaction, causing frequent diarrhea and melena. The causes have not been identified andthere is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active
phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine
drugs like Pentasa and steroids.
On October 1, 2008, KYORIN Pharmaceutical Co., Ltd. merged Nisshin Kyorin Pharmaceutical Co.,
Ltd. into KYORIN Pharmaceutical Co., Ltd. we will exclusively market Pentasa® Tablets 250,Pentasa® Enema 1g and Pentasa® Tablets 500 and will make an ongoing contribution to the treatmentof inflammatory bowel diseases by providing the latest information, including peripheral information.

* Adherence is more about patients’ taking responsibility in following the appropriate procedures for the therapy theyreceive, than it is about following the directions of physicians or pharmacists.

For further information, contact:
KYORIN Co.,Ltd
Management Planning Department
Telephone:+81-3-3293-3414
Fax:+81-3-3293-3454

Products Plofile1.Brand namePentasa® Tablets 500

Pentasa® Tablets 250

2.Nonproprietar
y nameMesalazine

Mesalazine

3.Indication

Ulcerative colitis (excluding severe Ulcerative colitis (excluding severecases) and Crohn’s diseasecases) and Crohn’s disease

4.Dosageand Ulcerative Colitis
Administration
Normally, for adult patients, a daily
dose of 1500 mg is divided into
three doses and is administeredorally after meals. The dose may bedecreased or increased according to
the age and symptoms while theupper limit is 2250 mg per day.
Normally, for infant patients, adaily dose of 30 to 60 mg/kg of
mesalazine is divided into threedoses and administered orally aftermeals. The dose may be decreased
or increased according to the age
and symptoms while the upper
limit is 2250 mg per day.

Ulcerative Colitis
Normally, for adult patients, a daily
dose of 1500 mg is divided into
three doses and is administeredorally after meals. The dose may bedecreased or increased according to
the age and symptoms while theupper limit is 2250 mg per day.
Normally, for infant patients, a daily
dose of 30 to 60 mg/kg of
mesalazine is divided into threedoses and administered orally aftermeals. The dose may be decreased
or increased according to the age
and symptoms while the upper limit
is 2250 mg per day.

5.NHI priceCrohn’s Disease
Normally, for adult patients, a daily
dose of 1500-3000 mg is divided
into three doses and is administeredorally after meals. The dose may bedecreased according to the age andsymptoms.
Normally, for infant patients, adaily dose of 40 to 60 mg/kg ofmesalazine is divided into threedoses and administered orally aftermeals. The dose may be decreased
or increased according to the ageand symptoms.
￥118.80 per tablet

Crohn’s Disease
Normally, for adult patients, a dailydose of 1500-3000 mg is divided
into three doses and is administeredorally after meals. The dose may bedecreased according to the age andsymptoms.
Normally, for infant patients, a daily
dose of 40 to 60 mg/kg of
mesalazine is divided into threedoses and administered orally aftermeals. The dose may be decreased
or increased according to the ageand symptoms.
￥59.40 per tablet

6.Packaging

PTP 100 tablets

PTP 100,500 tablets

Reference:1.Bland namePentasa® Enema 1g

2.Indications

Ulcerative colitis (excluding severe cases)

3.Dosageand Normally, for adult patients, a bottle (1 g mesalazine) as a daily dose is injected
Administration
through the rectal route. The dose may be decreased according to the age andsymptoms.
￥872.90 per bottle (1g)4.NHI price
6.Packaging

100 ml ×7